Vaxine Pty Ltd - Adelaide, South Australia

+61 (0)420 878 911
queries@vaxine.net

Follow

Vaxine Vaxine
Skip to content
  • Home
  • About
    • About
    • People
  • Projects
  • Publications
  • News
  • Contact

Vaxine Pty Ltd - Adelaide, South Australia

+61 (0)420 878 911
queries@vaxine.net

Follow

Sitemap

Pages

  • About Us
    • People
    • Contact
      • News
        • Projects
          • Publications
            • Sitemap
              • Vaxine

                Categories

                • Vaxine Updates (RSS) (17)

                Posts

                • Australian-made coronavirus vaccine shows promise in clinical trials (0)
                • Can India prevent Covid-19 third wave? Global vaccine expert Professor Nikolai Petrovsky answers (0)
                • CinnaGen initiates a phase 3 clincial trial of Vaxine’s COVID-19 vaccine technology (0)
                • Commencement of phase 2 study of Covid-19 vaccine technology (0)
                • Efficacy of COVID-19 vaccines (Video) (0)
                • Flinders University scientists led by Tasmanian Professor Nikolai Petrovsky on track to have a vaccine by the end of the year (0)
                • Flinders University targets Covid-19 vaccine (0)
                • List of Vaxine Awards & Honours (0)
                • Next-Generation needle-free flu vaccines (0)
                • Our modeling paper “In silico comparison of SARS-COV-2 spike protein-ace2 binding affinities across species and implications for virus origin” published in Nature Scientific Reports (0)
                • Phase 2 trial results (0)
                • Professor Nikolai Petrovsky vaccines and biodefense Covid-19, flu and beyond (0)
                • Promising clinical trial of Vaxine’s Covid-19 vaccine technology. (0)
                • Recent paper on use of our ADVAX-CPG Adjuvant in Herpes Simplex virus vaccine development (0)
                • Sypharma partners with Vaxine to manufacture Covid-19 vaccine product (0)
                • TGA grants Provisional Determination to Vaxine for its COVID-19 Recombinant Protein Vaccine (0)
                • The first Covid-19 vaccine developed in the Southern Hemisphere enters phase 1 human trials in Adelaide (0)

                Projects

                  https://vaxine.net/wp-content/uploads/2022/03/cropped-logo.png

                  Vaxine is an Australian-based biotechnology company that over the last 20 years has developed an extensive portfolio of vaccines and immunotherapies, including vaccines against Covid-19, influenza, hepatitis B, and Japanese encephalitis plus immunotherapies against allergy and cancer.  Underlying all these successful vaccines is Vaxine’s powerful vaccine adjuvant technology plus its capabilities in applying artificial intelligence to rapid drug design.

                  • About
                  • People
                  • Projects
                  • Publications
                  • News
                  • Contact

                  News

                  • Phase 2 trial results April 22, 2022
                  • TGA grants Provisional Determination to Vaxine for its COVID-19 Recombinant Protein Vaccine April 1, 2022
                  • Efficacy of COVID-19 vaccines (Video) September 21, 2021
                  Read more

                  © 2022 Vaxine Pty Ltd. All rights reserved.
                  Made with ❤ by Howdy Innovation

                  